Daniel Luiz Gimenes
Research Subjects
Daniel Luiz Gimenes has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Augusto Tufi Hassan
Sociedade Brasileira de Mastologia
2 shared publications - Beatriz Baaklini Geronymo
Beneficência Portuguesa de São Paulo
2 shared publications - Daniel de Araujo Buttros
Department of Obstetrics and Gynecology, Botucatu Medical School, Sao Paulo State University-Unesp, Botucatu, Brazil
2 shared publications - Eduardo Carvalho Pessoa
Department of Obstetrics and Gynecology, Botucatu Medical School, Sao Paulo State University-Unesp, Botucatu, Brazil
2 shared publications - Fabio Bagnoli
Department of Obstetrics and Gynecology Irmandade da Santa Casa de Misericórdia de São Paulo São Paulo SP Brazil
2 shared publications - Fabricio Palermo Brenelli
Universidade Estadual de Campinas (UNICAMP)
2 shared publications
Latest Publications
- Open Access
2025 São Paulo Breast Symposium Guidelines: luminal breast cancer and axillary surgery
Introduction: This study aims to disseminate evidence-based expert consensus statements derived from the 2025 International Symposium on Breast Diseases of Inland São Paulo (SIMIP), addressing four critical areas in breast cancer management: (1) initial treatment strategies for luminal breast cancer with imaging-positive (iN1) and clinically positive axilla (cN1); (2) therapeutic approaches for estrogen receptor–low (ER-low) breast cancer; (3) optimal duration of adjuvant endocrine therapy (ET) in luminal tumors; and (4) criteria for omitting axillary surgery in early breast cancer. Methods: The 2025 São Paulo Breast Diseases Symposium was a two-day event held in São Paulo, Brazil, involving 110 panelists, including 99 mastologists (90%) and 11 professionals from related fields (pathology, breast imaging, radiotherapy, and clinical oncology). Panelists were selected based on recognized expertise, defined by at least 10 years of clinical experience or significant academic contribution. Four priority thematic axes were identified through a pre-symposium survey of Brazilian and South American specialists. Each topic was introduced by a 10-minute evidence-based lecture followed by a 50-minute technical debate. Anonymous electronic voting was conducted via a secure online platform during hybrid sessions, with consensus defined as agreement by ≥75% of participants. Results: For patients with imaging-positive axilla (iN1), 52% of panelists preferred upfront surgery, without reaching consensus. In clinically positive axilla (cN1), treatment choice between upfront surgery and neoadjuvant chemotherapy varied according to age and menopausal status, supported by 57% of voters, also without consensus. A consensus of 84% was achieved to manage ER-low breast cancer similarly to triple-negative disease, using chemotherapy combined with endocrine therapy. Regarding endocrine therapy duration, consensus was reached for 7–10 years in high-risk Luminal B tumors (97%) and for 5 years in low-risk Luminal A tumors (95%). Omission of axillary surgery was supported by 85% of panelists in patients with tumors ≤2 cm, clinically node-negative disease (cT1N0), hormone receptor-positive/HER2-negative tumors, and negative axillary ultrasound findings. Conclusions: These expert consensus statements support personalized, multidisciplinary strategies to optimize oncologic outcomes while minimizing morbidity. Consensus favors extended endocrine therapy for high-risk luminal disease, shorter therapy for low-risk tumors, combined chemotherapy and endocrine therapy for ER-low disease, and omission of axillary surgery in carefully selected early breast cancer cases. Management of iN1 and cN1 disease should remain individualized based on clinical and biological factors, particularly in Brazil, where late-stage presentation remains frequent.
Open Access2025 São Paulo Breast Symposium Guidelines: luminal breast cancer and axillary surgery
Introduction: This study aims to disseminate evidence-based expert consensus statements derived from the 2025 International Symposium on Breast Diseases of Inland São Paulo (SIMIP), addressing four critical areas in breast cancer management: (1) initial treatment strategies for luminal breast cancer with imaging-positive (iN1) and clinically positive axilla (cN1); (2) therapeutic approaches for estrogen receptor–low (ER-low) breast cancer; (3) optimal duration of adjuvant endocrine therapy (ET) in luminal tumors; and (4) criteria for omitting axillary surgery in early breast cancer. Methods: The 2025 São Paulo Breast Diseases Symposium was a two-day event held in São Paulo, Brazil, involving 110 panelists, including 99 mastologists (90%) and 11 professionals from related fields (pathology, breast imaging, radiotherapy, and clinical oncology). Panelists were selected based on recognized expertise, defined by at least 10 years of clinical experience or significant academic contribution. Four priority thematic axes were identified through a pre-symposium survey of Brazilian and South American specialists. Each topic was introduced by a 10-minute evidence-based lecture followed by a 50-minute technical debate. Anonymous electronic voting was conducted via a secure online platform during hybrid sessions, with consensus defined as agreement by ≥75% of participants. Results: For patients with imaging-positive axilla (iN1), 52% of panelists preferred upfront surgery, without reaching consensus. In clinically positive axilla (cN1), treatment choice between upfront surgery and neoadjuvant chemotherapy varied according to age and menopausal status, supported by 57% of voters, also without consensus. A consensus of 84% was achieved to manage ER-low breast cancer similarly to triple-negative disease, using chemotherapy combined with endocrine therapy. Regarding endocrine therapy duration, consensus was reached for 7–10 years in high-risk Luminal B tumors (97%) and for 5 years in low-risk Luminal A tumors (95%). Omission of axillary surgery was supported by 85% of panelists in patients with tumors ≤2 cm, clinically node-negative disease (cT1N0), hormone receptor-positive/HER2-negative tumors, and negative axillary ultrasound findings. Conclusions: These expert consensus statements support personalized, multidisciplinary strategies to optimize oncologic outcomes while minimizing morbidity. Consensus favors extended endocrine therapy for high-risk luminal disease, shorter therapy for low-risk tumors, combined chemotherapy and endocrine therapy for ER-low disease, and omission of axillary surgery in carefully selected early breast cancer cases. Management of iN1 and cN1 disease should remain individualized based on clinical and biological factors, particularly in Brazil, where late-stage presentation remains frequent.
- Open Access
Triple-negative breast cancer: 2025 consensus guidelines
Objective: To disseminate the clinical guidelines established at the 2025 São Paulo Breast Diseases Symposium regarding the management of early triple-negative breast cancer (TNBC). Methods: The symposium convened 110 panelists, predominantly mastologists from São Paulo (101 mastologists, of which 94 from São Paulo and 7 from other regions: 1 from Bahia [Northeast], 2 from Rio Grande do Sul [South], 1 from Minas Gerais, 2 from Goiânia [central region], and 1 from Fortaleza [Northeast]), plus 6 oncologists, 2 pathologists, and 1 radiotherapist (all from São Paulo). Four priority topics were presented in evidence-based lectures, followed by technical discussions and anonymous electronic voting by all panelists. Consensus was defined as ≥75% agreement. Results: Voting showed 40% support for T1cN0 as the cutoff for upfront surgery, 16% for T2N0, but no consensus was reached. Consensus was achieved for using tumor-infiltrating lymphocytes (TILs) as an adjunct biomarker to guide initial systemic treatment (83%) and for sentinel lymph node biopsy (SLNB) as standard following neoadjuvant chemotherapy (NACT) (78%). Post-mastectomy radiotherapy was recommended even after pathological complete response (pCR) by 72%, though without consensus. Conclusions: The 2025 São Paulo Breast Diseases Symposium established guidelines for early TNBC management. Consensus was achieved for using TILs as an adjunct biomarker (83%) and SLNB as standard post-NACT (78%), while upfront surgery cutoff (40% for T1cN0) and radiotherapy omission post-pCR (72%) did not reach consensus, reflecting heterogeneous practices and the need for individualized approaches and further research.
Open AccessTriple-negative breast cancer: 2025 consensus guidelines
Objective: To disseminate the clinical guidelines established at the 2025 São Paulo Breast Diseases Symposium regarding the management of early triple-negative breast cancer (TNBC). Methods: The symposium convened 110 panelists, predominantly mastologists from São Paulo (101 mastologists, of which 94 from São Paulo and 7 from other regions: 1 from Bahia [Northeast], 2 from Rio Grande do Sul [South], 1 from Minas Gerais, 2 from Goiânia [central region], and 1 from Fortaleza [Northeast]), plus 6 oncologists, 2 pathologists, and 1 radiotherapist (all from São Paulo). Four priority topics were presented in evidence-based lectures, followed by technical discussions and anonymous electronic voting by all panelists. Consensus was defined as ≥75% agreement. Results: Voting showed 40% support for T1cN0 as the cutoff for upfront surgery, 16% for T2N0, but no consensus was reached. Consensus was achieved for using tumor-infiltrating lymphocytes (TILs) as an adjunct biomarker to guide initial systemic treatment (83%) and for sentinel lymph node biopsy (SLNB) as standard following neoadjuvant chemotherapy (NACT) (78%). Post-mastectomy radiotherapy was recommended even after pathological complete response (pCR) by 72%, though without consensus. Conclusions: The 2025 São Paulo Breast Diseases Symposium established guidelines for early TNBC management. Consensus was achieved for using TILs as an adjunct biomarker (83%) and SLNB as standard post-NACT (78%), while upfront surgery cutoff (40% for T1cN0) and radiotherapy omission post-pCR (72%) did not reach consensus, reflecting heterogeneous practices and the need for individualized approaches and further research.
- Open Access
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Revista Brasileira de Epidemiologia
- Vol. 26, e230028
Molecular subtypes as a prognostic breast cancer factor in women users of the São Paulo public health system, Brazil
Objective: This study aimed to analyze the prognosis of women with breast cancer by molecular subtypes, sociodemographic variables, and clinical and treatment characteristics. Methods: This hospital-based retrospective cohort study analyzed 1,654 women over 18 years of age diagnosed with invasive breast cancer from 2000 to 2018. Data were extracted from Brazil’s Oncocenter Foundation of São Paulo. The variables analyzed were age, histology, molecular subtypes, clinical staging, treatment type, and diagnosis-to-treatment time. Cox regression analysis was applied to estimate death risk. Results: Women with HER-2-positive (nonluminal) and triple-negative molecular subtypes were more than twice more likely to be at risk of death, with adjusted hazard ratio — HRadj=2.30 (95% confidence interval — 95%CI 1.34–3.94) and HRadj=2.51 (95%CI 1.61–3.92), respectively. A delayed treatment associated with an advanced clinical stage at diagnosis increased fourfold the risk of death (HRadj=4.20 (95%CI 2.36–7.49). Conclusion: In summary, besides that interaction between advanced clinical stage and longer time between diagnosis and treatment, HER-2-positive (nonluminal) and triple-negative phenotypes were associated with a worse prognosis. Therefore, actions to reduce barriers in diagnosis and treatment can provide better outcome, even in aggressive phenotypes.
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Revista Brasileira de Epidemiologia
- Vol. 26, e230028
Open AccessMolecular subtypes as a prognostic breast cancer factor in women users of the São Paulo public health system, Brazil
Objective: This study aimed to analyze the prognosis of women with breast cancer by molecular subtypes, sociodemographic variables, and clinical and treatment characteristics. Methods: This hospital-based retrospective cohort study analyzed 1,654 women over 18 years of age diagnosed with invasive breast cancer from 2000 to 2018. Data were extracted from Brazil’s Oncocenter Foundation of São Paulo. The variables analyzed were age, histology, molecular subtypes, clinical staging, treatment type, and diagnosis-to-treatment time. Cox regression analysis was applied to estimate death risk. Results: Women with HER-2-positive (nonluminal) and triple-negative molecular subtypes were more than twice more likely to be at risk of death, with adjusted hazard ratio — HRadj=2.30 (95% confidence interval — 95%CI 1.34–3.94) and HRadj=2.51 (95%CI 1.61–3.92), respectively. A delayed treatment associated with an advanced clinical stage at diagnosis increased fourfold the risk of death (HRadj=4.20 (95%CI 2.36–7.49). Conclusion: In summary, besides that interaction between advanced clinical stage and longer time between diagnosis and treatment, HER-2-positive (nonluminal) and triple-negative phenotypes were associated with a worse prognosis. Therefore, actions to reduce barriers in diagnosis and treatment can provide better outcome, even in aggressive phenotypes.